What is the current valuation of the Swine Vaccine Market as of 2024?

The Swine Vaccine Market was valued at 4.31 USD Billion in 2024. Read More

What is the projected market valuation for the Swine Vaccine Market in 2035?

The market is projected to reach 6.805 USD Billion by 2035. Read More

What is the expected CAGR for the Swine Vaccine Market during the forecast period 2025 - 2035?

The expected CAGR for the Swine Vaccine Market during 2025 - 2035 is 4.24%. Read More

Which companies are considered key players in the Swine Vaccine Market?

Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. Read More

What are the main types of vaccines in the Swine Vaccine Market and their valuations?

Live Attenuated Vaccines are valued at 2.4 USD Billion, while Inactivated Vaccines are at 1.8 USD Billion. Read More

How does the market segment for disease targets break down in terms of valuation?

Porcine Reproductive and Respiratory Syndrome is valued at 2.4 USD Billion, followed by Classical Swine Fever at 1.5 USD Billion. Read More

What are the different administration routes for swine vaccines and their market values?

Intramuscular administration is valued at 2.4 USD Billion, while Oral administration is at 1.2 USD Billion. Read More

Which end users dominate the Swine Vaccine Market?

Farms are the dominant end users, valued at 3.205 USD Billion. Read More

What is the valuation of subunit vaccines in the Swine Vaccine Market?

Subunit Vaccines are valued at 1.2 USD Billion. Read More

How does the market for toxoid vaccines compare to other vaccine types?

Toxoid Vaccines are valued at 1.4 USD Billion, indicating a competitive position among vaccine types. Read More

Swine Vaccine Market

ID: MRFR/HC/40740-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Swine Vaccine Market Research Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines), By Disease Target (Porcine Reproductive and Respiratory Syndrome, Classical Swine Fever, Porcine Parvovirus Infection, Swine Influenza), By Administration Route (Intramuscular, Subcutaneous, Oral, Intranasal), By End User (Veterinary Hospitals, Research Institutions, Farms) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 Live Attenuated Vaccines
4.1.2 Inactivated Vaccines
4.1.3 Subunit Vaccines
4.1.4 Toxoid Vaccines
4.2 Healthcare, BY Disease Target (USD Billion)
4.2.1 Porcine Reproductive and Respiratory Syndrome
4.2.2 Classical Swine Fever
4.2.3 Porcine Parvovirus Infection
4.2.4 Swine Influenza
4.3 Healthcare, BY Administration Route (USD Billion)
4.3.1 Intramuscular
4.3.2 Subcutaneous
4.3.3 Oral
4.3.4 Intranasal
4.4 Healthcare, BY End User (USD Billion)
4.4.1 Veterinary Hospitals
4.4.2 Research Institutions
4.4.3 Farms
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Zoetis (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Merck Animal Health (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Boehringer Ingelheim (DE)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Elanco Animal Health (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Ceva Santé Animale (FR)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Huvepharma (BG)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Vetoquinol (FR)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Phibro Animal Health (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 IDT Biologika (DE)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY DISEASE TARGET
6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.6 US MARKET ANALYSIS BY END USER
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY DISEASE TARGET
6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.10 CANADA MARKET ANALYSIS BY END USER
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY DISEASE TARGET
6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.15 GERMANY MARKET ANALYSIS BY END USER
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY DISEASE TARGET
6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.19 UK MARKET ANALYSIS BY END USER
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY DISEASE TARGET
6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.23 FRANCE MARKET ANALYSIS BY END USER
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY DISEASE TARGET
6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.27 RUSSIA MARKET ANALYSIS BY END USER
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY DISEASE TARGET
6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.31 ITALY MARKET ANALYSIS BY END USER
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY DISEASE TARGET
6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.35 SPAIN MARKET ANALYSIS BY END USER
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE TARGET
6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY DISEASE TARGET
6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.44 CHINA MARKET ANALYSIS BY END USER
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY DISEASE TARGET
6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.48 INDIA MARKET ANALYSIS BY END USER
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY DISEASE TARGET
6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.52 JAPAN MARKET ANALYSIS BY END USER
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE TARGET
6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY DISEASE TARGET
6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.60 MALAYSIA MARKET ANALYSIS BY END USER
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY DISEASE TARGET
6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.64 THAILAND MARKET ANALYSIS BY END USER
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY DISEASE TARGET
6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.68 INDONESIA MARKET ANALYSIS BY END USER
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY DISEASE TARGET
6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.72 REST OF APAC MARKET ANALYSIS BY END USER
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY DISEASE TARGET
6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.77 BRAZIL MARKET ANALYSIS BY END USER
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY DISEASE TARGET
6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.81 MEXICO MARKET ANALYSIS BY END USER
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY DISEASE TARGET
6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.85 ARGENTINA MARKET ANALYSIS BY END USER
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TARGET
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TARGET
6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TARGET
6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY DISEASE TARGET
6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.102 REST OF MEA MARKET ANALYSIS BY END USER
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY DISEASE TARGET, 2024 (% SHARE)
6.112 HEALTHCARE, BY DISEASE TARGET, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.2.4 BY END USER, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.3.4 BY END USER, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.4.4 BY END USER, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.5.4 BY END USER, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.6.4 BY END USER, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.7.4 BY END USER, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.8.4 BY END USER, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.9.4 BY END USER, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.10.4 BY END USER, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.11.4 BY END USER, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.12.4 BY END USER, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.13.4 BY END USER, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.14.4 BY END USER, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.15.4 BY END USER, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.16.4 BY END USER, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.17.4 BY END USER, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.18.4 BY END USER, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.19.4 BY END USER, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.20.4 BY END USER, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.21.4 BY END USER, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.22.4 BY END USER, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.23.4 BY END USER, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.24.4 BY END USER, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.25.4 BY END USER, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.26.4 BY END USER, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.27.4 BY END USER, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.28.4 BY END USER, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.29.4 BY END USER, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY DISEASE TARGET, 2025-2035 (USD Billion)
7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7.30.4 BY END USER, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines

Healthcare By Disease Target (USD Billion, 2025-2035)

Porcine Reproductive and Respiratory Syndrome
Classical Swine Fever
Porcine Parvovirus Infection
Swine Influenza

Healthcare By Administration Route (USD Billion, 2025-2035)

Intramuscular
Subcutaneous
Oral
Intranasal

Healthcare By End User (USD Billion, 2025-2035)

Veterinary Hospitals
Research Institutions
Farms

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓